Multiple Genetic Alterations within the PI3K Pathway Are Responsible for AKT Activation in Patients with Ovarian Carcinoma

被引:33
作者
De Marco, Carmela [1 ,2 ]
Rinaldo, Nicola [2 ]
Bruni, Paola [3 ]
Malzoni, Carmine [3 ]
Zullo, Fulvio [1 ]
Fabiani, Fernanda [1 ]
Losito, Simona [4 ]
Scrima, Marianna [1 ,2 ]
Zito Marino, Federica [4 ]
Franco, Renato [4 ]
Quintiero, Alfina [1 ]
Agosti, Valter [1 ]
Viglietto, Giuseppe [1 ,2 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy
[2] Inst Genet Res Gaetano Salvatore, Biogem Scarl, Avellino, Italy
[3] Casa Cura Malzoni Villa Platani, Avellino, Italy
[4] Fdn G Pascale, NCI, Naples, Italy
来源
PLOS ONE | 2013年 / 8卷 / 02期
关键词
SIGNALING PATHWAY; PHOSPHORYLATED AKT; THERAPEUTIC TARGET; PROGNOSTIC VALUE; PIK3CA GENE; MUTATIONAL ANALYSIS; PROTEIN EXPRESSION; PTEN EXPRESSION; IN-VITRO; CANCER;
D O I
10.1371/journal.pone.0055362
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is activated in multiple cancers including ovarian carcinoma (OC). However, the relative contribution of the single components within the PI3K pathway to AKT activation in OC is still unclear. We examined 98 tumor samples from Italian OC patients for alterations in the members of the PI3K pathway. We report that AKT is significantly hyperactive in OC compared to normal tissue (n = 93; p<0.0001) and that AKT activation is preferentially observed in the elderly (>58 years old; n = 93; p<0.05). The most frequent alteration is the overexpression of the p110 alpha catalytic subunit of PI3K (63/93, similar to 68%); less frequent alterations comprise the loss of PTEN (24/89, 27%) and the overexpression of AKT1 (18/96, 19%) or AKT2 (11/88,12.5%). Mutations in the PIK3CA or KRAS genes were detected at lower frequency (12% and 10%, respectively) whereas mutations in AKT1 or AKT2 genes were absent. Although many tumors presented a single lesion (28/93, of which 23 overexpressed PIK3CA, 1 overexpressed AKT and 4 had lost PTEN), many OC (35/93) presented multiple alterations within the PI3K pathway. Apparently, aberrant PI3K signalling was mediated by activation of the canonical downstream AKT-dependent mTOR/S6K1/4EBP1 pathway and by regulation of expression of oncogenic transcription factors that include HMGA1, JUN-B, FOS and MYC but not by AKT-independent activation of SGK3. FISH analysis indicated that gene amplification of PIK3CA, AKT1 and AKT2 (but not of PI3KR1) and the loss of PTEN are common and may account for changes in the expression of the corresponding proteins. In conclusion, our results indicate that p110 alpha overexpression represents the most frequent alteration within the PI3K/AKT pathway in OC. However, p110 alpha overexpression may not be sufficient to activate AKT signalling and drive ovarian tumorigenesis since many tumors overexpressing PI3K presented at least one additional alteration.
引用
收藏
页数:18
相关论文
共 71 条
  • [1] PIK3CA alterations in Middle Eastern ovarian cancers
    Abubaker, Jehad
    Bavi, Prashant
    Al-Haqawi, Wael
    Jehan, Zeenath
    Munkarah, Adnan
    Uddin, Shahab
    Al-Kuraya, Khawla S.
    [J]. MOLECULAR CANCER, 2009, 8
  • [2] AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
    Altomare, DA
    Wang, HQ
    Skele, KL
    De Rienzo, A
    Klein-Szanto, AJ
    Godwin, AK
    Testa, JR
    [J]. ONCOGENE, 2004, 23 (34) : 5853 - 5857
  • [3] Oncogenic Role of the E3 Ubiquitin Ligase NEDD4-1, a PTEN Negative Regulator, in Non-Small-Cell Lung Carcinomas
    Amodio, Nicola
    Scrima, Marianna
    Palaia, Lucia
    Salman, Ali Naeem
    Quintiero, Alfina
    Franco, Renato
    Botti, Gerardo
    Pirozzi, Pino
    Rocco, Gaetano
    De Rosa, Nicla
    Viglietto, Giuseppe
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2010, 177 (05) : 2622 - 2634
  • [4] [Anonymous], CANC TOP OV CANC
  • [5] [Anonymous], MOL CLONING LAB MANU
  • [6] [Anonymous], BLAUSTEINS PATHOLOGY
  • [7] [Anonymous], CANC TREATMENT RES O
  • [8] [Anonymous], OV CANC
  • [9] Ovarian surface epithelium: Biology, endocrinology, and pathology
    Auersperg, N
    Wong, AST
    Choi, KC
    Kang, SK
    Leung, PCK
    [J]. ENDOCRINE REVIEWS, 2001, 22 (02) : 255 - 288
  • [10] KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay
    Auner, Veronika
    Kriegshaeuser, Gernot
    Tong, Dan
    Horvat, Reinhard
    Reinthaller, Alexander
    Mustea, Alexander
    Zeillinger, Robert
    [J]. BMC CANCER, 2009, 9